Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Juno Therapeutics, Inc.
Traded as NASDAQ: JUNO
Industry Biotechnology
Founded 2013
Headquarters Seattle, WA
Key people

Hans Bishop (CEO & President)
Steve Harr, M.D. (CFO)
Hyam Levitsky, M.D. (CSO)

Mark Gilbert, M.D. (CMO)
Website junotherapeutics.com

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.

Investment goal date:
Dividends reinvested
Juno Therapeutics, Inc. JUNO report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-08
--
--
Q4 2017
2018-02-27
--
--
Q3 2017
2017-11-01
-0.7300
0.0000
Q2 2017
2017-08-03
-0.7400
-0.9600
Q1 2017
2017-05-04
-0.7100
-0.7900
Q4 2016
2017-03-01
-0.6500
-0.5100
Q3 2016
2016-11-09
-0.5700
-0.5600
Q2 2016
2016-08-04
-0.6400
-0.6400
Q1 2016
2016-05-09
-0.7800
-0.7200
Q4 2015
2016-02-29
-0.5300
-0.8900
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Arrowpoint Asset Management, LLC
1527706
BAILLIE GIFFORD & CO
11197863
BlackRock Fund Advisors
2146963
BlackRock Inc.
4183793
BlackRock Institutional Trust Company, N.A.
1830981
Capital World Investors
2130000
Crestline Management, LP
17348799
FIRST TRUST ADVISORS LP
1377667
FMR LLC
1918592
GOLDMAN SACHS GROUP INC
898160
Mitsubishi UFJ Trust & Banking Corp
924650
MORGAN STANLEY
860048
STATE STREET CORP
3013630
TEMASEK HOLDINGS (PRIVATE) LTD
915750
Vanguard Group, Inc
6153812
Major Shareholders
Name Relationship
Total Shares
Holding stocks